ライフサイエンスコーパス: ciprofloxacin

1 tics (moxifloxacin followed by ofloxacin and ciprofloxacin).

2 guish between the efficacy of ampicillin and ciprofloxacin.

3 hromycin, trimethoprim-sulfamethoxazole, and ciprofloxacin.

4 ceftriaxone, 95% to penicillin, and 99.9% to ciprofloxacin.

5 the sensitivity of Pseudomonas aeruginosa to ciprofloxacin.

6 omonas phage cocktail alone or combined with ciprofloxacin.

7 abrogated by cotreatment with the antibiotic ciprofloxacin.

8 P. aeruginosa EE and highly synergistic with ciprofloxacin.

9 e resistant to penicillin, tetracycline, and ciprofloxacin.

10 and the proportion of isolates resistant to ciprofloxacin.

11 n of Neisseria gonorrhoeae susceptibility to ciprofloxacin.

12 se yields active enzyme that is resistant to ciprofloxacin.

13 sseria gonorrhoeae isolates are resistant to ciprofloxacin.

14 ed decreased susceptibility or resistance to ciprofloxacin.

15 istant or showed decreased susceptibility to ciprofloxacin.

16 tes of Indonesian origin were susceptible to ciprofloxacin.

17 k for uveitis compared with moxifloxacin and ciprofloxacin.

18 ction against hydrogen peroxide, bleach, and ciprofloxacin.

19 p and RadD function increases sensitivity to ciprofloxacin.

20 idents taking amoxicillin/clavulanic acid or ciprofloxacin.

21 bration of the carboxyl group present in the ciprofloxacin.

22 ethoxazole, amoxicillin/clavulanic acid, and ciprofloxacin.

23 reement with two antibiotics, ampicillin and ciprofloxacin.

24 n-polymyxin B-gramicidin in the Philippines; ciprofloxacin 0.3% in India).

25 cin disks detected all isolates resistant to ciprofloxacin (0% very major error) and yielded false re

26 36), gentamicin (0.89; 95%CI: 0.06-1.84) and ciprofloxacin (0%).

27 ARD-3150 (3 mL liposome encapsulated ciprofloxacin 135 mg and 3 mL free ciprofloxacin 54 mg)

28 52 (42%) to levofloxacin, 20 of 54 (37%) to ciprofloxacin, 16 of 47 (34%) to moxifloxacin, and 3 of

29 e observed by Etest, and 11 minor errors for ciprofloxacin (19.0%) and 20 (34.5%) for levofloxacin we

30 hours but were prevented by combination with ciprofloxacin (2.5 x minimum inhibitory concentration).

31 greater activity than the parent antibiotic ciprofloxacin (30 mg/kg, 90.6 mumol/kg) given in multipl

32 The resistance rate was 39% against ciprofloxacin, 44% against TMP-SMX, and 25% against cefu

33 lled trial, we studied retreatment with oral ciprofloxacin 500 mg or matched placebo twice daily for

34 ose of the study was to assess the effect of ciprofloxacin (500 mg twice daily for 10 days) or clinda

35 apsulated ciprofloxacin 135 mg and 3 mL free ciprofloxacin 54 mg) or 6 mL placebo (3 mL dilute empty

36 12 days for povidone-iodine and 17 days for ciprofloxacin (95% CI, -35.2 to 3.2 days).

37 with resistance based on characteristics of ciprofloxacin (A), azithromycin (B), and ceftriaxone (C)

38 eftriaxone [a 3rd-generation cephalosporin], ciprofloxacin [a fluoroquinolone], and gentamicin [an am

39 For example, in the case of ciprofloxacin, a higher amount of compound was located i

40 The drug derivatives, consisting of ciprofloxacin, a perfluoroaryl ring, and a phenyl ring l

41 h a single treatment of chitosan followed by ciprofloxacin administration had a marked effect on redu

42 /6 mice after treatment with the antibiotics ciprofloxacin, amoxicillin, or a cocktail of ampicillin/

43 Modeling of the transit of ciprofloxacin, an antibiotic of choice for treating Camp

44 longer expected to survive as 19.7 hours for ciprofloxacin and 26.5 hours for levofloxacin.

45 ociation was noted between clarithromycin or ciprofloxacin and adverse cardiac outcomes.

46 Using ciprofloxacin and ampicillin as well defined test cases,

47 model of shigellosis to test the efficacy of ciprofloxacin and ampicillin.

48 k for the detection of two antibiotic drugs, ciprofloxacin and ampicillin.

49 % (95/541) and 50.6% (274/541) resistance to ciprofloxacin and azithromycin, respectively.

50 ral Asia sublineage exhibiting resistance to ciprofloxacin and azithromycin.

51 line acidifications and filtrations afforded ciprofloxacin and ciprofloxacin hydrochloride.

52 etermination of oxolinic acid, danofloxacin, ciprofloxacin and enrofloxacin by micellar liquid chroma

53 oxacin; 0.0050-50 mug L(-1) for norfloxacin, ciprofloxacin and enrofloxacin; and 0.010-50 mug L(-1) f

54 Typhi strains with high-level resistance to ciprofloxacin and gatifloxacin had emerged.

55 radation and does not affect the activity of ciprofloxacin and gentamicin.

56 n, the essential agreement was 100% for both ciprofloxacin and levofloxacin and the CA was 81.0% and

57 ow window following fever onset during which ciprofloxacin and levofloxacin are fully effective treat

58 2019, these revisions include changes to the ciprofloxacin and levofloxacin breakpoints for the Enter

59 ublished revisions to the Enterobacteriaceae ciprofloxacin and levofloxacin breakpoints.

60 Categorical agreements for the ciprofloxacin and levofloxacin Etests were 89.6 and 83.7

61 xplore the effect of delaying treatment with ciprofloxacin and levofloxacin on efficacy.

62 tered 10 hours after fever onset, 10 days of ciprofloxacin and levofloxacin treatment remained very e

63 Treatment with ciprofloxacin and levofloxacin was initiated from 0 to u

64 Ciprofloxacin and levofloxacin were found to be >90% eff

65 Ciprofloxacin and levofloxacin, 2 fluoroquinolone antimi

66 y was performed for the bioquantification of ciprofloxacin and marbofloxacin via HPTLC-Bacillus subti

67 .6 ng and 2 ng of the synthetic antibiotics, ciprofloxacin and marbofloxacin, respectively.

68 hioprine and the fluoroquinolone antibiotics ciprofloxacin and ofloxacin interact with UVA radiation

69 23.11%, 15.22% and 10.14% for pyrazinamide, ciprofloxacin and ofloxacin, respectively (P < 0.01).

70 atients in the high exposure arm, the use of ciprofloxacin and piperacillin/tazobactam was 51% and 75

71 Exposure to the antibiotics ciprofloxacin and trimethoprim leads to the formation of

72 espite the bacteria's relative resistance to ciprofloxacin and where an equivalent dose of pulmonary-

73 In particular, ciprofloxacin and, to a lesser extent, azithromycin, cef

74 g or in the absence of antibiotic treatment (ciprofloxacin and/or metronidazole).

75 forward protocol from a perfluoroaryl azide, ciprofloxacin, and an aldehyde in acetone at room temper

76 ells to cis-DA led to a loss of tolerance to ciprofloxacin, and an increase of the bacterial fluoresc

77 of three different substrates (norfloxacin, ciprofloxacin, and enoxacin) by varying the pH between 6

78 Here, we show that the FQ drugs norfloxacin, ciprofloxacin, and enrofloxacin are powerful iron chelat

79 , inhibitors of bacterial gyrase, GSK299423, ciprofloxacin, and etoposide exhibited 15-, 57-, and 3-f

80 e resistance was observed for tetracyclines, ciprofloxacin, and linezolid.

81 e different emerging contaminants (caffeine, ciprofloxacin, and propranolol) and two model compounds

82 antibiotics such as kanamycin, streptomycin, ciprofloxacin, and tetracycline.

83 nce determinants for different beta-lactams, ciprofloxacin, and tetracyclines on multiple occasions.

84 Current use of moxifloxacin or ciprofloxacin appears to increase the risk for uveitis.

85 the safety and efficacy of inhaled liposomal ciprofloxacin (ARD-3150) in two phase 3 trials.

86 d 34 days (interquartile range 17-62) in the ciprofloxacin arm, which was not significantly different

87 amenting progeny with enhanced resistance to ciprofloxacin as the parent filament dies.

88 tions benefit from additional treatment with ciprofloxacin, at Day 14.Methods: In a multicenter, rand

89 Ciprofloxacin AUC24 was 16.9 mg*h/L in the prednisone pr

90 We report the modular formulation of ciprofloxacin-based pure theranostic nanodrugs that disp

91 Among known mast cell MRGPRX2 agonists ciprofloxacin but not PMX-53 was functional on basophils

92 eptibility to the fluoroquinolone antibiotic ciprofloxacin by increased efflux.

93 levant antimicrobials (colistin, imipenem or ciprofloxacin) by Transposon Directed Insertion-site Seq

94 rcalating poison, and that the antibacterial ciprofloxacin can poison yeast topoisomerase II.

95 We synthesized several ciprofloxacin-carbohydrate conjugates and established a

96 hat sublethal doses of the common antibiotic ciprofloxacin cause severe drops in bacterial abundance.

97 tics in the presence of various antibiotics (ciprofloxacin, cefixime, and amoxycillin), drug efficacy

98 minimum inhibitory concentrations (MICs) to ciprofloxacin, cefixime, ceftriaxone, and cefpodoxime.

99 mples) of N. gonorrhoeae were susceptible to ciprofloxacin, ceftriaxone, and azithromycin and compris

100 ial activities of various antibiotics (i.e., ciprofloxacin, ceftriaxone, and tetracycline) against Es

101 tive intermediates of azithromycin (AZI) and ciprofloxacin (CFC) after water chlorination.

102 Antibiotics, such as ofloxacin (OFX) and ciprofloxacin (CFX), are often detected in considerable

103 the SOS response by the genotoxic antibiotic ciprofloxacin changes the E. coli rod shape into multich

104 cross-resistance to other antibiotics (i.e., ciprofloxacin, chloramphenicol, and tetracycline).

105 itive bacterial isolates were susceptible to ciprofloxacin, chloramphinicol, amoxicillin-clavulanate

106 nvestigated as an antimicrobial enhancer for ciprofloxacin (CIP) against a wild-type PA biofilm (stra

107 oring of fluoroquinolone antibiotics such as ciprofloxacin (CIP) and norfloxacin (NOR) for their quan

108 dsorption and electron transfer reactions of ciprofloxacin (CIP) in a dynamic column containing nanos

109 The antibiotic ciprofloxacin (CIP) is extensively employed to treat inf

110 In this study, interactions of Ciprofloxacin (CIP), a fluoroquinolone antibiotic with t

111 tolytic fate of the chlortetracycline (CTC), ciprofloxacin (CIP), roxarsone (ROX), and sulfamethoxazo

112 Overall ciprofloxacin (CIP), trimethoprim-sulfamethoxazole (SXT)

113 ility of many poorly soluble drugs including ciprofloxacin (Cip).

114 dinitrophenyl (DNP) moiety to the C7 end of ciprofloxacin (Cip-DNP) reduced protection due to resist

115 e report that the fluoroquinolone antibiotic ciprofloxacin (cipro) induces mutations by triggering tr

116 quatic environments, enrofloxacin (ENRO) and ciprofloxacin (CIPRO), were chosen as nonresonant molecu

117 for susceptibility to ampicillin, cefazolin, ciprofloxacin, colistin, gentamicin, meropenem, and tetr

118 Moreover, phage/ciprofloxacin combinations were highly synergistic, kill

119 chitosan in conjunction with the antibiotic ciprofloxacin completely eradicates UPEC from the urinar

120 for nitrate reduction in regions with toxic ciprofloxacin concentrations (i.e., 50x minimum inhibito

121 er, we tested the effect of a broad range of ciprofloxacin concentrations on antibiotic resistance de

122 cribe a novel osteoadsorptive bisphosphonate-ciprofloxacin conjugate (BV600022), utilizing a "target

123 ta-(azepan-1-yl)alanine, and fluorescent and ciprofloxacin-containing amino acid derivatives.

124 Patients with ciprofloxacin-containing regimens had higher risk of inv

125 for azithromycin; P = .040) and did not (for ciprofloxacin) correlate with V. cholerae suppression.

126 sily applicable by user for the detection of ciprofloxacin (CPX) molecule in water resources.

127 ized the cells to ionizing radiation, UV and ciprofloxacin damage, indicating that these two genes ha

128 into stable nanoaggregates that transformed ciprofloxacin derivatives into AIE-active luminogens.

129 nhibitory or subinhibitory concentrations of ciprofloxacin did induce the SOS response, but not when

130 Levels of induction of toxin production by ciprofloxacin differed among the strains tested, with mo

131 ing reactions were observed: enrofloxacin-to-ciprofloxacin, difloxacin-to-sarafloxacin, and pefloxaci

132 ound evaluation method, levofloxacin but not ciprofloxacin disk diffusion yielded an acceptable minor

133 olates are difficult to detect with standard ciprofloxacin disk diffusion, and plasmid-mediated resis

134 For ciprofloxacin disk diffusion, the categorical agreement

135 82.6%, 67.8%, and 23.5% were susceptible to ciprofloxacin, erythromycin, and penicillin, respectivel

136 Ciprofloxacin exposure shows an almost 2-fold change thr

137 Ciprofloxacin exposure shows an almost two-fold change t

138 genetic interactions for survival to AZT or ciprofloxacin exposure were observed between RadA and kn

139 aracteristics and anti-leukemic treatment on ciprofloxacin exposure, the area under the concentration

140 haracteristics and antileukemic treatment on ciprofloxacin exposure, the area under the concentration

141 We examined whether further therapy with ciprofloxacin for incompletely resolved COPD exacerbatio

142 roquinolone-resistant mutant, the potency of ciprofloxacin for inhibition of supercoiling and stabili

143 nificantly enhanced therapeutic index versus ciprofloxacin for the treatment of osteomyelitis in vivo

144 ged ceftriaxone, cefixime, azithromycin, and ciprofloxacin geometric mean minimum inhibitory concentr

145 of randomization, 57% of the patients in the ciprofloxacin group and 53% in the placebo group experie

146 Spectra acquired from dissolved ciprofloxacin had peaks related to the ionised carboxyl

147 liana mutant resistant to the quinolone drug ciprofloxacin has a point mutation in ATGYRA.

148 ed and high yielding continuous synthesis of ciprofloxacin has been developed, which employs a chemos

149 xone > tautetracycline) again indicated that ciprofloxacin has more bactericidal activity than the ot

150 quinolone antimicrobial agents, particularly ciprofloxacin, has increased in recent decades.

151 sensing of biologically active drug molecule ciprofloxacin hydrochloride (CFX).

152 elivery systems consisting of the antibiotic ciprofloxacin hydrochloride and FDA-approved polymers ar

153 s and filtrations afforded ciprofloxacin and ciprofloxacin hydrochloride.

154 lates were susceptible in vitro to amikacin, ciprofloxacin, imipenem, linezolid, moxifloxacin, and tr

155 of Staphylococcus aureus with the antibiotic ciprofloxacin in a large-scale evolution experiment.

156 ms, and pleiotropic effects of resistance to ciprofloxacin in Acinetobacter baumannii populations.

157 sition of individual liposomes encapsulating ciprofloxacin in dissolved and nanocrystalline form.

158 R in differentiating the liposome containing ciprofloxacin in dissolved or nanocrystalline form.

159 ly classified as susceptible or resistant to ciprofloxacin in less than 10 min.

160 , nitrofurantoin, trimethoprim/sulfonamides, ciprofloxacin) in the 30 days after the assessment and C

161 to clinically relevant antibiotics, such as ciprofloxacin, in P. aeruginosa biofilms and that this e

162 Also, the addition of ciprofloxacin induced a highly selective fluorescence en

163 In conclusion, this study demonstrates a ciprofloxacin-induced reversible reduction of the normal

164 Stx2a levels after ciprofloxacin induction were lower for PA2 than for the

165 (P = .028) and an increase at 5 months after ciprofloxacin intake to 4.88% +/- 1.02.

166 whole tendon (from baseline to 10 days after ciprofloxacin intake, 130 arbitrary units [au] +/- 8 to

167 ter ciprofloxacin intake, and 5 months after ciprofloxacin intake, 134 au +/- 8, 105 au +/- 5, and 11

168 th a decrease from baseline to 10 days after ciprofloxacin intake, 4.74% +/- 0.75 to 4.50% +/- 0.23,

169 he tendon insertion (baseline, 10 days after ciprofloxacin intake, and 5 months after ciprofloxacin i

170 of GAG content in the Achilles tendon after ciprofloxacin intake.

171 n at baseline and 10 days and 5 months after ciprofloxacin intake.

172 Ciprofloxacin is a broad-spectrum antibiotic that is rec

173 Ciprofloxacin is a recommended treatment for Shigella in

174 meropenem, piperacillin-tazobactam, and oral ciprofloxacin is associated with decreased bla(CTX-M) (8

175 Bactericidal activity comparable to ciprofloxacin is demonstrated against clinically relevan

176 in biofilms, phenazine-dependent survival on ciprofloxacin is diminished in mutants lacking these enz

177 In this context, ciprofloxacin is part of the first-line of countermeasur

178 Our results suggest that resistance to ciprofloxacin is responsive to short-term variation in a

179 , for the three antibiotics, indicating that ciprofloxacin is the most effective against this E. coli

180 Ciprofloxacin is the standard treatment in self-therapy

181 Ciprofloxacin is used as antimicrobial prophylaxis in pe

182 MICs ranging from 0.12 to 0.25 mg/liter for ciprofloxacin (just above the wild-type MIC of </=0.06 m

183 udies, human-equivalent doses of gentamicin, ciprofloxacin, levofloxacin, and doxycycline were admini

184 re MIC tested by broth microdilution against ciprofloxacin, levofloxacin, and ofloxacin and by disk d

185 patient and post-discharge) fluoroquinolone (ciprofloxacin, levofloxacin, moxifloxacin) exposure was

186 ed resistance phenotypes against ampicillin, ciprofloxacin, meropenem, and vancomycin.

187 Antibiosis with Ciprofloxacin/Metronidazole (n = 12, P = .01), Piperacil

188 higher Shannon indices (P = .01) compared to Ciprofloxacin/Metronidazole with/without systemic antibi

189 maintained microbiome diversity compared to Ciprofloxacin/Metronidazole with/without systemic antibi

190 cs, Rifaximin with systemic antibiotics, and Ciprofloxacin/Metronidazole with/without systemic antibi

191 including 111 with intermediate or resistant ciprofloxacin MICs mediated by a variety of resistance m

192 Fifty-eight Enterobacteriaceae isolates with ciprofloxacin MICs of 0.5 mug/ml or 1.0 mug/ml on initia

193 untreated controls) and was comparable with ciprofloxacin monotherapy.

194 re to colistin (n = 35), imipenem (n = 1) or ciprofloxacin (n = 1) in addition to known resistance de

195 to groups that received the prophylaxis with ciprofloxacin (n = 112) or saline solution (n = 114, pla

196 fever within 78 hours and were treated with ciprofloxacin (n = 27) or levofloxacin (n = 29) at vario

197 complete recovery were randomized to receive ciprofloxacin (n = 72) or placebo (n = 72).

198 n the spectra of liposomal sample containing ciprofloxacin nanocrystals.

199 owever, we discovered that in the absence of ciprofloxacin, neutralization of Stx1a enhanced the viru

200 evaluate anaphylactoid reactions induced by ciprofloxacin, norfloxacin, lomefloxacin, moxifloxacin,

201 Ciprofloxacin, ofloxacin, and pefloxacin disks detected

202 ppears that clindamycin has more impact than ciprofloxacin on the intestinal microbiota.

203 two common antibiotics, oxytetracycline and ciprofloxacin, on the protistan and bacterial communitie

204 Exposure to ciprofloxacin or clindamycin had a strong effect on the

205 the normal microbiota to be normalized after ciprofloxacin or clindamycin treatment differed for vari

206 ients completed the trial (90.7%), receiving ciprofloxacin or the control, with no statistically sign

207 Patients were randomized 1:1 to oral (ciprofloxacin) or intravenous (ceftriaxone) antibiotics

208 me in the presence or absence of penicillin, ciprofloxacin, or doxycycline.

209 nce of colloids promotes the breakthrough of ciprofloxacin (over 90% sorbed on colloids) from ~4% to

210 ociated with the prevalence of resistance to ciprofloxacin (P < .05).

211 trimethoprim-sulfamethoxazole (P = .01), and ciprofloxacin (P = .03) than that from group A.

212 xacin, ciprofloxacin plus hydrocortisone, or ciprofloxacin plus dexamethasone) or neomycin plus hydro

213 floxacin, ciprofloxacin plus hydrocortisone, ciprofloxacin plus dexamethasone, and neomycin plus hydr

214 ocortisone, and 2.00 (95% CI, 1.18-3.41) for ciprofloxacin plus dexamethasone.

215 ocortisone, and 2.30 (95% CI, 1.09-4.87) for ciprofloxacin plus dexamethasone.

216 for ofloxacin, 1.94 (95% CI, 1.32-2.85) for ciprofloxacin plus hydrocortisone, and 2.00 (95% CI, 1.1

217 for ofloxacin, 2.24 (95% CI, 1.03-4.85) for ciprofloxacin plus hydrocortisone, and 2.30 (95% CI, 1.0

218 Included ear drops were ofloxacin, ciprofloxacin plus hydrocortisone, ciprofloxacin plus de

219 cluded ear drops were quinolones (ofloxacin, ciprofloxacin plus hydrocortisone, or ciprofloxacin plus

220 rmacokinetics and pharmacodynamics (PKPD) of ciprofloxacin prophylaxis in a pediatric ALL population.

221 ermine the pharmacokinetics and -dynamics of ciprofloxacin prophylaxis in a pediatric ALL population.

222 did not differ significantly with vs without ciprofloxacin prophylaxis.

223 Upon addition of ciprofloxacin, PVD showed new UV-vis absorption bands at

224 unit of PVD generates a converging cleft for ciprofloxacin recognition with LOD and LOQ of 7.13muM an

225 In contrast to ciprofloxacin, religation of the cleaved DNA did not occ

226 t solids may cause slight underestimation of ciprofloxacin removal efficiency.

227 We assessed their ciprofloxacin resistance and ability to induce secretion

228 etection of genetic variants known to confer ciprofloxacin resistance in Bacillus anthracis, Yersinia

229 The trend toward increasing rates of ciprofloxacin resistance in S. sonnei, in addition to pl

230 aled that, comparing 2004-2009 to 2010-2012, ciprofloxacin resistance increased among domestic infect

231 T-90, ST-91, and ST-97 (n = 162; 94.2%); and ciprofloxacin resistance was associated with NG-STAR ST-

232 erococcus, and Streptococcus), with multiple ciprofloxacin-resistance mutations in drug target genes

233 ly 2000s and the subsequent global spread of ciprofloxacin-resistant (cipR) Shigella sonnei from 2010

234 children (19%) and 8 mothers (20%) excreted ciprofloxacin-resistant E. coli at least once.

235 effective management strategy to help reduce ciprofloxacin-resistant E. coli in cattle within the Uni

236 least 1 member whose stool specimen yielded ciprofloxacin-resistant E. coli on culture.

237 Ciprofloxacin-resistant E. coli were usually resistant t

238 y children and their mothers commonly harbor ciprofloxacin-resistant E. coli with pathogenic potentia

239 n feedlots contributing to fecal shedding of ciprofloxacin-resistant E. coli, but a single month of E

240 lings within all regions tested positive for ciprofloxacin-resistant E. coli, but prevalence differed

241 ated with increased cattle fecal shedding of ciprofloxacin-resistant E. coli.

242 ing reductions in bovine fecal prevalence of ciprofloxacin-resistant E. coli.

243 rococcus faecalis/faecium (VREfc/VREfm), and ciprofloxacin-resistant Escherichia coli (CipREc) coloni

244 eedlots is associated with the prevalence of ciprofloxacin-resistant Escherichia coli in cattle and t

245 tool specimens were cultured selectively for ciprofloxacin-resistant gram-negative bacteria.

246 erase IV and display potent activity against ciprofloxacin-resistant Gram-negative pathogens.

247 riving the current intercontinental surge of ciprofloxacin-resistant S. sonnei and is capable of esta

248 However, ciprofloxacin-resistant S. sonnei are being increasingly

249 s into a global phylogeny, we found that all ciprofloxacin-resistant S. sonnei formed a single clade

250 encing on a collection of 60 contemporaneous ciprofloxacin-resistant S. sonnei isolated in four count

251 y hub for the recent international spread of ciprofloxacin-resistant S. sonnei.

252 a COPD exacerbation, an additional course of ciprofloxacin resulted in no additional benefit compared

253 Trapping of reaction intermediates with ciprofloxacin revealed complexes undergoing catalysis.

254 en between 3 weeks and 12 months with either ciprofloxacin-rifampin or with doxycycline alone or doxy

255 Similarly, resistance to ciprofloxacin rose from 2.5% to 31.1% in E coli, from 1.

256 The three product antibiotics, namely ciprofloxacin, sarafloxacin, and norfloxacin, were found

257 Ciprofloxacin showed superior microbiological, but not c

258 The standard-of-care drug ciprofloxacin suffers from severe systemic side effects

259 genome sequencing of isolates with decreased ciprofloxacin susceptibility (DCS) was performed.

260 rates of multidrug resistance and decreased ciprofloxacin susceptibility (DCS) were 37.8% and 37.2%,

261 e evaluated a real-time PCR assay to predict ciprofloxacin susceptibility using residual DNA from the

262 , with one isolate also exhibiting decreased ciprofloxacin susceptibility.

263 d that cipR S. sonnei displaced the resident ciprofloxacin-susceptible (cipS) lineage while rapidly a

264 ide polymorphisms (SNP) and deletions within ciprofloxacin targeted genes.

265 cies of three antibiotics (sulfamethoxazole, ciprofloxacin, tetracycline) in pilot- and full-scale bi

266 f antibiotics from different classes, namely ciprofloxacin, tetracycline, trimethoprim, and erythromy

267 t at subminimal inhibitory concentrations of ciprofloxacin the bacterial filament divides asymmetrica

268 bacteria to nutrient broth and penicillin or ciprofloxacin, the authors were able to distinguish in s

269 he risk gradually increased with duration of ciprofloxacin therapy: six of 384 in patients not expose

270 ase that is the target of the quinolone drug ciprofloxacin; this has important consequences for plant

271 The antibiotic-treated plants translocated ciprofloxacin through their tissues to roots, shoots, an

272 ntibiotics tested ranged from 0.05 mug/L for ciprofloxacin to 1,250 mug/L for erythromycin.

273 Conjugation of ciprofloxacin to lectin probes enabled biofilm accumulat

274 evels and targeted an intracellular depot of ciprofloxacin to the alveolar macrophage compartment tha

275 and PDO300 to multiple antibiotics including ciprofloxacin, tobramycin, tetracycline, and gentamicin.

276 and Stx2a was virulent in streptomycin- and ciprofloxacin-treated mice and that mice were protected

277 cies replacement through cross housing after ciprofloxacin treatment established resilience to a seco

278 regions and influence metabolic responses to ciprofloxacin treatment.

279 rovided by DNA topoisomerase mutations under ciprofloxacin treatment.

280 Removal of acetaminophen, ciprofloxacin, trimethoprim, propranolol, and carbamazep

281 studied seasonal variation in resistance to ciprofloxacin, trimethoprim-sulfamethoxazole, and ampici

282 olled concentration gradients of nitrate and ciprofloxacin under anoxic conditions in order to evalua

283 Ciprofloxacin used at study entry independently predicte

284 cellent adsorption capacity (235.6 mg/g) for ciprofloxacin via combined adsorption interaction mechan

285 nferiority trial to compare prophylaxis with ciprofloxacin vs placebo in patients with a pancreatic c

286 of Neisseria with reduced susceptibility to ciprofloxacin was 93%, cefpodoxime 84%, cefixime 31%, an

287 rate-bound method, the minor error rate for ciprofloxacin was acceptable, but minor error rates for

288 The association constant (Ka) of PVD with ciprofloxacin was calculated to be as low as 1.40x10(5)M

289 an equivalent dose of pulmonary-administered ciprofloxacin was ineffective.

290 residence time of 9 min, the sodium salt of ciprofloxacin was prepared from simple building blocks v

291 Oxidation of ranitidine, cimetidine, and ciprofloxacin was primarily attributed to reaction with

292 In empiric therapy, ciprofloxacin was the first choice of drug (27%), follow

293 tetracycline, norfloxacylin, ceftriaxone and ciprofloxacin were observed among Gram negative bacteria

294 15%, n = 590) with reduced susceptibility to ciprofloxacin were obtained, among which 14 harboured PM

295 cumulate in a process that is accelerated by ciprofloxacin, while the wild type (WT) is retained in t

296 ng from changes in antimicrobial efficacy of ciprofloxacin with 92-94% accuracy.

297 pment of an antibiotic prodrug that combines ciprofloxacin with a beta-lactamase-cleavable motif.

298 istant to metronidazole, aminoglycosides and ciprofloxacin with L. acidophilus being susceptible to p

299 urthermore, our data show that resistance to ciprofloxacin within S. sonnei may be globally attribute

300 Ideally, use of ciprofloxacin would be prefaced with AR determination to